{'fraction_non_alphanumeric': 0.025892857142857145, 'fraction_numerical': 0.007142857142857143, 'mean_word_length': 6.326797385620915, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Precise medical decision making in geriatric anti-depressant therapy

ABSTRACT Introduction: Human aging is characterized by increasing vulnerability not only to diseases, but also to the treatments applied to that diseases. Geriatric depression is a frequent mental disorder often requiring pharmacological treatment, which commonly is added to other medications taken to treat chronic or acute co-morbidities. The challenges of appropriate treatment of elderly are increasingly recognized as an urgent health problem. Areas covered: The challenges of appropriate geriatric anti-depressant prescription, and the role of novel tools developed by Precision Medicine. The data were obtained searching in MEDLINE: pharmacokinetics, pharmacodynamics, pharmacogenetics, antidepressants, drug-drug interactions and elderly, in the period 1994–2016. Expert commentary: The Precision Medicine approach take advantage by novel decision-supporting tools, as pharmacogenomic testing, drug-drug interactions evaluation and therapeutic drug monitoring, allowing to improve informed-decision making in prescription of antidepressants.